Clearside Biomedical Stock Today
| CLSD Stock | USD 0.91 0.01 1.09% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Clearside Biomedical is trading at 0.91 as of the 27th of February 2025, a 1.09 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.86. Clearside Biomedical has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of January 2025 and ending today, the 27th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of June 2016 | Category Healthcare | Classification Health Care |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. The company has 75.84 M outstanding shares of which 777.77 K shares are currently shorted by private and institutional investors with about 5.16 trading days to cover. More on Clearside Biomedical
Moving against Clearside Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Clearside Stock Highlights
| President | Rafael Andino | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsClearside Biomedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Clearside Biomedical's financial leverage. It provides some insight into what part of Clearside Biomedical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clearside Biomedical (CLSD) is traded on NASDAQ Exchange in USA. It is located in 900 North Point Parkway, Alpharetta, GA, United States, 30005 and employs 30 people. Clearside Biomedical is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.26 M. Clearside Biomedical conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 75.84 M outstanding shares of which 777.77 K shares are currently shorted by private and institutional investors with about 5.16 trading days to cover.
Clearside Biomedical currently holds about 29.03 M in cash with (18.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.
Check Clearside Biomedical Probability Of Bankruptcy
Ownership AllocationClearside Biomedical holds a total of 75.84 Million outstanding shares. Clearside Biomedical shows 8.0 percent of its outstanding shares held by insiders and 20.21 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Clearside Ownership Details
Clearside Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Assenagon Asset Management Sa | 2024-12-31 | 131.9 K | |
| Pnc Financial Services Group Inc | 2024-12-31 | 108.2 K | |
| Captrust Financial Advisors | 2024-12-31 | 101.2 K | |
| Brown Wealth Management, Llc | 2024-12-31 | 100 K | |
| Northeast Financial Consultants, Inc | 2024-12-31 | 93 K | |
| Citadel Advisors Llc | 2024-09-30 | 71.6 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 59 K | |
| Newman Dignan & Sheerar Inc | 2024-12-31 | 30.1 K | |
| Synovus Financial Corp | 2024-12-31 | 30 K | |
| Vanguard Group Inc | 2024-12-31 | 2.8 M | |
| Carmignac Gestion | 2024-12-31 | 1.9 M |
Clearside Biomedical Historical Income Statement
Clearside Stock Against Markets
Clearside Biomedical Corporate Management
| MD MBA | Chief AdvisorRetina | Profile | |
| Jenny Kobin | Head Relations | Profile | |
| FRCOphth FRCS | Chief Officer | Profile | |
| Leslie Zacks | Chief Compliance Officer, General Counsel | Profile | |
| Charles Deignan | Chief Officer | Profile | |
| Susan Coultas | Chief Officer | Profile | |
| Leslie JD | Secretary | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth 0.208 | Return On Assets | Return On Equity |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.